The therapeutic value of adjuvant chemotherapy after concurrent chemoradiotherapy for locally advanced cervical cancer

• Published in: Gynecologic and obstetric investigation
• Main Authors: Wang, Ya-Nan, Zhong, Mei-Ling, Liang, Mei-Rong, Yang, Jian-Tong, Zeng, Si-Yuan
• Format: Journal Article
• Language: English
• Published: Switzerland 01.11.2023
• ISSN: 1423-002X
• DOI: 10.1159/000533122

The aim of this study was to evaluate the therapeutic value and treatment-related complications of adjuvant chemotherapy after concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). The medical records of LACC patients who underwent CCRT were reviewed retrospectively. A total of 1,138 patients with LACC who had been treated at our hospital between January 2013 and December 2017 were included in the study and classified into two groups: the CCRT group, comprising 726 patients who had received only CCRT, and the CCRT + ACT group, comprising 412 patients who had received three cycles of adjuvant chemotherapy after CCRT. 39 patients in the CCRT group and 50 patients in the CCRT + ACT group had undergone lymphadenectomy, which revealed pathology-positive lymph nodes in 22 patients and 35 patients, respectively. Progression-free survival (PFS), overall survival (OS) and adverse events were compared. The median follow-up time was 61 months (range: 2-96 months). No significant differences in PFS and OS were found between the two groups (p ＞ 0.05), but more grade 3-4 acute hematologic toxicities were observed in the CCRT + ACT group than in the CCRT group (24.8% vs. 31.8%, p = 0.01). A subgroup analysis of patients with pathology-positive lymph nodes showed that the five-year PFS and OS rates were 76.5% and 74.9%, respectively, for the CCRT + ACT group and 45.0% and 49.2%, respectively, for the CCRT group; the differences were statistically significant (p = 0.015 and 0.042, respectively). First, the sample size of the subgroup of patients with pathology-positive lymph nodes was too small for a confirmative conclusion. The heterogeneous population and the selection bias resulting from the retrospective design were the other flaws of our study. The application of adjuvant chemotherapy after concurrent chemoradiotherapy may be worth investigating further for women with LACC and pathology-positive lymph nodes, but this approach is associated with an increase in acute hematology toxicities.